Becton, Dickinson and Company (NYSE:BDX) is included among the The 11 Best Rising Dividend Stocks to Buy Right Now.
On May 11, Barclays raised its price recommendation for Becton, Dickinson and Company (NYSE:BDX) to $204 from $202. He reiterated an Overweight rating on the stock following the company’s fiscal second-quarter results. The firm said Becton achieved solid operating growth and exceeded consensus expectations. The analyst also noted that the company appears to be well positioned in the current macroeconomic environment.
During the fiscal second quarter 2026 earnings call, Chairman, CEO and President Thomas Polen said revenue increased 2.6% to $4.7 billion. It noted double-digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration. At the same time, Polen said the results were partly offset by continued pressure on Alaris, vaccines and China, which together accounted for less than 10% of total revenue.
Polen also said the company gained about 50 basis points of market share during the quarter and about 150 basis points so far this year in the Alaris business. In the BioPharma Systems segment, he noted that BD secured several important agreements with long-term customers, including two next-generation GLP-1 programs. He added that biologics are now expected to account for around 55% of the segment’s revenue.
Discussing regulatory matters, Polen said the company voluntarily placed its ChloraPrep and PurPrep products on hold in the U.S. after the FDA issued a warning letter related to the El Paso facility. He added that the testing process related to the issue was expected to last about three weeks and said no signs of patient safety had been identified.
Becton, Dickinson and Company (NYSE:BDX) develops, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, researchers and clinical laboratories worldwide.
While we recognize the potential of BDX as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 12 Best Microcap Dividend Stocks to Buy Now and 10 Best Stocks to Buy Now for a $1 Million Portfolio
Disclosure: None. Follow Insider Monkey on Google News.